Citius Oncology Inc. reported fiscal third-quarter results that disappointed the investment community, with the company’s stock declining 10.05% in pre-market trading. Quarterly revenue reached $1.5 million, substantially trailing the analyst consensus forecast of $12.52 million. The company posted a loss of $0.34 per share against expectations for earnings of $0.03 per share. For the nine-month period ended June 30, 2026, the company generated $7.1 million in total revenue.
Despite the revenue shortfall, commercial indicators for LYMPHIR, the company’s primary product, demonstrated expanding market traction. Institutional vial orders increased 31% sequentially to 926 units from 708 in the previous quarter, and momentum accelerated further into July when institutions ordered 383 vials, representing a 25% increase over the prior quarter’s average monthly volume and marking the strongest month since launch. The number of institutions prescribing and ordering LYMPHIR reached 44, with new ordering institutions climbing 80% compared with the previous quarter.
Chairman and Chief Executive Officer Leonard Mazur characterized the commercial trajectory positively, noting that formulary approvals, institutional adoption, and unit demand were accelerating and provided confidence for the remainder of the fiscal year. The company achieved near-universal payer coverage with no reimbursement denials or prior-authorization obstacles reported. Supporting this expansion, Citius Oncology added 21 field-based professionals and eight medical science liaisons during the quarter.
The commercial expansion drove significant increases in operating expenses. Quarterly operating costs reached $9.7 million compared with $4.9 million in the prior-year period, primarily reflecting commercial operations growth. This resulted in a net quarterly loss of $8.9 million, or $0.08 per share, compared with a loss of $5.4 million, or $0.08 per share, in the corresponding prior-year quarter. As of June 30, 2026, the company held cash and cash equivalents of $16.6 million.
Market observers will monitor whether accelerating institutional adoption and vial orders translate into stronger revenue growth in the coming periods, as the significant revenue miss offset positive indicators from the product’s commercial rollout.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI